Concomitant risk factors in reports of torsades de pointes associated with macrolide use: review of the United States Food and Drug Administration Adverse Event Reporting System.
about
Azithromycin and the risk of cardiovascular deathDrug-induced QT interval prolongation and torsades de pointes: Role of the pharmacist in risk assessment, prevention and managementImpact of Age and Sex on QT Prolongation in Patients Receiving PsychotropicsDrug-drug interactions and QT prolongation as a commonly assessed cardiac effect - comprehensive overview of clinical trialsAntimicrobial safety: focus on fluoroquinolonesTime-to-Onset Analysis of Drug-Induced Long QT Syndrome Based on a Spontaneous Reporting System for Adverse Drug EventsTelithromycin-induced digoxin toxicity and electrocardiographic changes.Use of azithromycin and risk of ventricular arrhythmia.Azithromycin, cardiovascular risks, QTc interval prolongation, torsade de pointes, and regulatory issues: A narrative review based on the study of case reports.Erythromycin, QTc interval prolongation, and torsade de pointes: Case reports, major risk factors and illness severityA novel genetic modifier for clarithromycin-related cardiac arrhythmia risk?Life-threatening bradyarrhythmia after massive azithromycin overdose.Use of clarithromycin and roxithromycin and risk of cardiac death: cohort studyPrevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation.Advantages of azithromycin over erythromycin in improving the gastric emptying half-time in adult patients with gastroparesisQT prolongation and torsade de pointes induced by fluoroquinolones: infrequent side effects from commonly used medications.Adverse drug event monitoring at the Food and Drug Administration.Clinical relevance and management of drug-related QT interval prolongation.Clinical manifestation of macrolide antibiotic toxicity in CKD and dialysis patients.Cardiac risks associated with antibiotics: azithromycin and levofloxacinCare transitions: a leverage point for safe and effective medication use in older adults--a mini-reviewNo proarrhythmic properties of the antibiotics Moxifloxacin or Azithromycin in anaesthetized dogs with chronic-AV block.Effects of cardioactive drugs on human induced pluripotent stem cell derived long QT syndrome cardiomyocytesAntimicrobial-associated QT interval prolongation: pointes of interest.Incidence of Sustained Ventricular Tachycardia in Patients with Prolonged QTc After the Administration of Azithromycin: A Retrospective Study.Azithromycin and risk of sudden cardiac death: guilty as charged or falsely accused?Risk of cardiovascular events, arrhythmia and all-cause mortality associated with clarithromycin versus alternative antibiotics prescribed for respiratory tract infections: a retrospective cohort study.QT prolongation in the intensive care unit: commonly used medications and the impact of drug-drug interactions.Drug-induced QT-interval prolongation: considerations for clinicians.Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases.Antibiotic-induced cardiac arrhythmias.Oritavancin, a new lipoglycopeptide antibiotic: results from a thorough QT study.Targeted Cancer Therapies and QT Interval Prolongation: Unveiling the Mechanisms Underlying Arrhythmic Complications and the Need for Risk Stratification Strategies.Therapeutic challenges posed by critical drug-drug interactions in cystic fibrosis.Macrolide and fluoroquinolone mediated cardiac arrhythmias: clinical considerations and comprehensive review.Effects of macrolide antibiotics on rat embryonic heart function in vitro.[Treatment of postoperative impairment of gastrointestinal motility, cholangitis and pancreatitis].The cardiovascular and pharmacokinetic profile of dofetilide in conscious telemetered beagle dogs and cynomolgus monkeys.Risk factors for drug-induced long-QT syndrome.Epidemiology of symptomatic drug-induced long QT syndrome and Torsade de Pointes in Germany.
P2860
Q24604355-7283C55E-39AE-4A3B-BEC6-F93998D26EE5Q26747032-0A9DB2B5-CED3-46DA-9EE7-D475F17A29CAQ26801837-13EA2001-B40C-4FAF-90A2-B090790D184BQ28071256-5244A88B-33B6-4976-9268-42C2D8F6C198Q28255152-8B8877C6-DA15-4D32-8324-57204D886155Q28554594-3F1072BB-7DE2-4A91-86C7-0907D482A953Q33153871-23DE6C01-61DC-4165-B228-AEA9E3E7A30EQ33566195-7889D9EF-2338-4451-91A8-5D2E2C2BD90CQ33695227-B6E8EA48-4555-42FC-BF44-C0F3E4A45F39Q33810580-5685335C-E5FB-4FA1-9D26-5CDAD8EC5D1CQ33810586-5CCA6C74-1329-479F-81AD-294BA44F2498Q33993853-041B1C95-501F-47A1-8A49-848FB8626CCDQ34041767-EBE40784-AA30-4590-A9DC-CB385194B55FQ34100661-34AA661F-E97C-40D3-960A-52D0BEABCB72Q34298283-13FD8DD4-99B7-49DF-93EF-944F34B8C865Q34634216-9E339E34-9EE5-4A62-886C-A1ED6FD65EAEQ34740872-2F7E167C-220D-47B4-B561-5239187470B3Q35186542-192E4D5D-2D5F-42EA-A041-F2193E9F9257Q35310541-D25D1DC8-49DD-4E49-A198-33406AD6D71DQ35502601-B4726FBA-21F2-4CB9-88F2-650C296929B5Q35775812-2B818F3A-8502-4062-BF2B-6340E0D8D4BFQ36054313-BBEF5A2D-C531-4D68-B7B1-1B5B11B803DAQ36632323-F8CEEA73-2FE2-4581-9702-B6919BB991A2Q36655034-534FEB2B-ACB1-4EC1-9954-091231A367EAQ36761496-931601C2-FC3C-47DA-9D80-C402D935C3B9Q37531455-77A95E61-A81C-416D-81D8-C199D1EF93E0Q37612235-F41E78A9-6956-4D6E-9FFD-29C75944E389Q37727223-7806E76A-D92E-44EE-8A03-C450127E4C8EQ37767425-736AD961-A343-4DBC-9CB6-4888409432B7Q37959271-0E2999A2-B62B-46E2-A0D1-D1488C87E96EQ38178757-644119C4-6C14-417A-9ADB-B48819DBDDEBQ38485341-DEC82BAD-67C6-4F0E-ADED-532F654AEB76Q38956949-C60E1B62-CED0-438B-8459-12F6521504DCQ38962747-E9D00168-9449-4F86-927A-4DB834539EB2Q40108685-3B19B22A-0B8F-44A9-8683-BAC9269FFF31Q40209609-C5B709FF-F7E4-469C-B409-3E0B02222484Q41221240-DDBE11C6-9813-4811-9438-993C99A6F3BBQ41255343-9A380DC9-9AF2-46BE-BE86-9B02AE917150Q42340044-6088A686-5507-4BAD-B010-D5E33ADF98BDQ46455559-9C2A1CC4-DE30-4169-A7D0-A23E3EF1F93D
P2860
Concomitant risk factors in reports of torsades de pointes associated with macrolide use: review of the United States Food and Drug Administration Adverse Event Reporting System.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Concomitant risk factors in re ...... dverse Event Reporting System.
@ast
Concomitant risk factors in re ...... dverse Event Reporting System.
@en
Concomitant risk factors in re ...... dverse Event Reporting System.
@nl
type
label
Concomitant risk factors in re ...... dverse Event Reporting System.
@ast
Concomitant risk factors in re ...... dverse Event Reporting System.
@en
Concomitant risk factors in re ...... dverse Event Reporting System.
@nl
prefLabel
Concomitant risk factors in re ...... dverse Event Reporting System.
@ast
Concomitant risk factors in re ...... dverse Event Reporting System.
@en
Concomitant risk factors in re ...... dverse Event Reporting System.
@nl
P2093
P2860
P356
P1476
Concomitant risk factors in re ...... dverse Event Reporting System.
@en
P2093
Douglas Shaffer
Joyce Korvick
Peter Honig
Sarah Singer
P2860
P304
P356
10.1086/340861
P407
P577
2002-06-19T00:00:00Z